QQQ   287.64 (-1.68%)
AAPL   146.63 (-0.80%)
MSFT   250.20 (-1.89%)
META   122.43 (-0.86%)
GOOGL   99.48 (-0.96%)
AMZN   91.01 (-3.31%)
TSLA   182.45 (-6.37%)
NVDA   166.10 (-1.58%)
NIO   12.80 (-2.51%)
BABA   90.52 (+0.51%)
AMD   73.62 (-1.81%)
T   18.75 (-1.42%)
MU   54.04 (-1.17%)
CGC   4.32 (+0.70%)
F   13.38 (-3.46%)
GE   84.66 (-2.56%)
DIS   95.93 (-3.52%)
AMC   7.45 (-8.81%)
PYPL   73.62 (-1.39%)
PFE   50.73 (-0.35%)
NFLX   312.59 (-2.44%)
QQQ   287.64 (-1.68%)
AAPL   146.63 (-0.80%)
MSFT   250.20 (-1.89%)
META   122.43 (-0.86%)
GOOGL   99.48 (-0.96%)
AMZN   91.01 (-3.31%)
TSLA   182.45 (-6.37%)
NVDA   166.10 (-1.58%)
NIO   12.80 (-2.51%)
BABA   90.52 (+0.51%)
AMD   73.62 (-1.81%)
T   18.75 (-1.42%)
MU   54.04 (-1.17%)
CGC   4.32 (+0.70%)
F   13.38 (-3.46%)
GE   84.66 (-2.56%)
DIS   95.93 (-3.52%)
AMC   7.45 (-8.81%)
PYPL   73.62 (-1.39%)
PFE   50.73 (-0.35%)
NFLX   312.59 (-2.44%)
QQQ   287.64 (-1.68%)
AAPL   146.63 (-0.80%)
MSFT   250.20 (-1.89%)
META   122.43 (-0.86%)
GOOGL   99.48 (-0.96%)
AMZN   91.01 (-3.31%)
TSLA   182.45 (-6.37%)
NVDA   166.10 (-1.58%)
NIO   12.80 (-2.51%)
BABA   90.52 (+0.51%)
AMD   73.62 (-1.81%)
T   18.75 (-1.42%)
MU   54.04 (-1.17%)
CGC   4.32 (+0.70%)
F   13.38 (-3.46%)
GE   84.66 (-2.56%)
DIS   95.93 (-3.52%)
AMC   7.45 (-8.81%)
PYPL   73.62 (-1.39%)
PFE   50.73 (-0.35%)
NFLX   312.59 (-2.44%)
QQQ   287.64 (-1.68%)
AAPL   146.63 (-0.80%)
MSFT   250.20 (-1.89%)
META   122.43 (-0.86%)
GOOGL   99.48 (-0.96%)
AMZN   91.01 (-3.31%)
TSLA   182.45 (-6.37%)
NVDA   166.10 (-1.58%)
NIO   12.80 (-2.51%)
BABA   90.52 (+0.51%)
AMD   73.62 (-1.81%)
T   18.75 (-1.42%)
MU   54.04 (-1.17%)
CGC   4.32 (+0.70%)
F   13.38 (-3.46%)
GE   84.66 (-2.56%)
DIS   95.93 (-3.52%)
AMC   7.45 (-8.81%)
PYPL   73.62 (-1.39%)
PFE   50.73 (-0.35%)
NFLX   312.59 (-2.44%)
NASDAQ:ALDX

Aldeyra Therapeutics - ALDX Stock Forecast, Price & News

$6.46
-0.06 (-0.92%)
(As of 12/5/2022 12:00 AM ET)
Add
Compare
Today's Range
$6.25
$6.52
50-Day Range
$5.08
$6.52
52-Week Range
$2.36
$7.99
Volume
372,897 shs
Average Volume
774,742 shs
Market Capitalization
$378.30 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.75

Aldeyra Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
194.1% Upside
$19.00 Price Target
Short Interest
Healthy
3.57% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.89mentions of Aldeyra Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.18) to ($1.20) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.16 out of 5 stars

Medical Sector

450th out of 1,033 stocks

Pharmaceutical Preparations Industry

200th out of 502 stocks

ALDX stock logo

About Aldeyra Therapeutics (NASDAQ:ALDX) Stock

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company’s clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.

Receive ALDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aldeyra Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ALDX Stock News Headlines

See More Headlines
Receive ALDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aldeyra Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ALDX Company Calendar

Last Earnings
10/27/2021
Today
12/05/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/16/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ALDX
Employees
15
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$19.00
High Stock Price Forecast
$28.00
Low Stock Price Forecast
$11.00
Forecasted Upside/Downside
+159.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-57,780,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.54 per share

Miscellaneous

Free Float
54,461,000
Market Cap
$378.30 million
Optionable
Optionable
Beta
1.27

Key Executives

  • Todd C. Brady (Age 48)
    M.D., Ph.D., Chief Executive Officer and Director
  • Joshua Reed (Age 47)
    Chief Financial Officer
  • David McMullin (Age 45)
    Chief Commercial Officer
  • James A. Gow (Age 53)
    M.D., Senior Vice President of Clinical Development
  • Stephen G. Machatha (Age 43)
    Ph.D., Senior Vice President, Technical Operation













ALDX Stock - Frequently Asked Questions

Should I buy or sell Aldeyra Therapeutics stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aldeyra Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ALDX shares.
View ALDX analyst ratings
or view top-rated stocks.

What is Aldeyra Therapeutics' stock price forecast for 2023?

4 Wall Street analysts have issued 12 month price objectives for Aldeyra Therapeutics' shares. Their ALDX share price forecasts range from $11.00 to $28.00. On average, they predict the company's stock price to reach $19.00 in the next twelve months. This suggests a possible upside of 194.1% from the stock's current price.
View analysts price targets for ALDX
or view top-rated stocks among Wall Street analysts.

How have ALDX shares performed in 2022?

Aldeyra Therapeutics' stock was trading at $4.00 at the beginning of the year. Since then, ALDX shares have increased by 61.5% and is now trading at $6.46.
View the best growth stocks for 2022 here
.

Are investors shorting Aldeyra Therapeutics?

Aldeyra Therapeutics saw a decline in short interest in November. As of November 15th, there was short interest totaling 2,000,000 shares, a decline of 8.3% from the October 31st total of 2,180,000 shares. Based on an average daily volume of 370,700 shares, the short-interest ratio is currently 5.4 days. Currently, 3.6% of the shares of the company are sold short.
View Aldeyra Therapeutics' Short Interest
.

When is Aldeyra Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 16th 2023.
View our ALDX earnings forecast
.

How were Aldeyra Therapeutics' earnings last quarter?

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) released its quarterly earnings results on Wednesday, October, 27th. The biotechnology company reported ($0.27) earnings per share for the quarter, missing analysts' consensus estimates of ($0.26) by $0.01. During the same period in the previous year, the firm posted ($0.23) earnings per share.

What other stocks do shareholders of Aldeyra Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aldeyra Therapeutics investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Sorrento Therapeutics (SRNE), KushCo (KSHB), Bionano Genomics (BNGO), Gran Tierra Energy (GTE), Zosano Pharma (ZSAN), Novan (NOVN), OrganiGram (OGI) and Pennsylvania Real Estate Investment Trust (PEI).

What is Aldeyra Therapeutics' stock symbol?

Aldeyra Therapeutics trades on the NASDAQ under the ticker symbol "ALDX."

Who are Aldeyra Therapeutics' major shareholders?

Aldeyra Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Perceptive Advisors LLC (19.38%), Vanguard Group Inc. (4.30%), Verition Fund Management LLC (4.12%), Knoll Capital Management LLC (3.21%), Eagle Asset Management Inc. (2.50%) and Prosight Management LP (2.07%). Insiders that own company stock include Life Sciences Maste Perceptive, Martin Joseph Joyce, Perceptive Advisors Llc, Richard Douglas and Todd C Brady.
View institutional ownership trends
.

How do I buy shares of Aldeyra Therapeutics?

Shares of ALDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aldeyra Therapeutics' stock price today?

One share of ALDX stock can currently be purchased for approximately $6.46.

How much money does Aldeyra Therapeutics make?

Aldeyra Therapeutics (NASDAQ:ALDX) has a market capitalization of $378.30 million. The biotechnology company earns $-57,780,000.00 in net income (profit) each year or ($1.11) on an earnings per share basis.

How can I contact Aldeyra Therapeutics?

Aldeyra Therapeutics' mailing address is 131 HARTWELL AVENUE SUITE 320, LEXINGTON MA, 02421. The official website for the company is www.ampliphibio.com. The biotechnology company can be reached via phone at 781-761-4904, via email at ir@ampliphibio.com, or via fax at 781-270-0630.

This page (NASDAQ:ALDX) was last updated on 12/5/2022 by MarketBeat.com Staff